GlobeNewswire: Todos Medical Ltd. Contains the last 10 of 252 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:00:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/12/22/2800853/0/en/Todos-Medical-Announces-Insolvency-Proceedings-in-Israel.html?f=22&fvtc=4&fvtv=45088Todos Medical Announces Insolvency Proceedings in Israel2023-12-22T22:28:34Z<![CDATA[NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, Israel, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), an innovative healthcare solutions company, today announced that a trustee was appointed (the “Trustee”) with respect to an insolvency order that was issued with respect to the Company in Israel related to a request for liquidation filed by the Company’s Founder and former Director, President & CEO Rami Zigdon.]]>https://www.globenewswire.com/news-release/2023/09/26/2749792/0/en/Todos-Medical-Provides-Corporate-Update-Retooling-to-Focus-on-Long-COVID-Epidemic.html?f=22&fvtc=4&fvtv=45088Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic2023-09-26T15:01:54Z<![CDATA[NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Todos Medical, Ltd. (OTCQB: TOMDF), an innovative healthcare solutions company, today provided a corporate update to its stakeholders centered on the Company’s efforts to retool and focus primarily on addressing the Long COVID epidemic that is affecting over 15 million Americans, over 6% of the adult US population, according to the US Centers for Disease Control. Todos intends to deploy medical foods to aid physicians in the dietary management of Long COVID, optimize immune support with nutritional supplements targeting the 3CL protease, and precision diagnostic panels to assist in the diagnosis and monitoring of Long COVID patients. A recent report by David Cutler of Harvard University estimates the annual Long COVID cost to the US economy is $3.7 trillion.]]>https://www.globenewswire.com/news-release/2023/08/30/2734315/0/en/Todos-Announces-Notice-of-Allowance-From-USPTO-for-Patent-Application-Covering-Use-of-Compositions-In-Tollovid-and-Tollovir-Ingredients.html?f=22&fvtc=4&fvtv=45088Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients2023-08-30T12:19:37Z<![CDATA[Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad’s lifelong work]]>https://www.globenewswire.com/news-release/2023/03/28/2635780/0/en/Todos-Medical-Enters-Into-Letter-of-Intent-for-Provista-Diagnostics-to-License-PCR-based-Sepsis-Diagnostic-Test-AcuSept-LDT-Rights-From-Acumen-Diagnostics.html?f=22&fvtc=4&fvtv=45088Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics2023-03-28T13:09:02Z<![CDATA[New York, NY, Alpharetta, GA, Tel Aviv, ISRAEL and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has entered into a letter of intent with Acumen Diagnostics Pte Ltd of Singapore for its CLIA/CAP-certified clinical testing lab Provista Diagnostics to license the laboratory developed test (LDT) rights to commercialize the sepsis PCR-based diagnostic test AcuSept® in the United States. AcuSept is a host (patient) immune response test that identifies 19 mRNA biomarkers of infection, sepsis and septic shock, and can be used to monitor patient response to treatment. Under the terms of the agreement, Provista will also conduct clinical validation studies on AcuSept® to generate the data in the United States to support Acumen Diagnostics’ 510(k) submission to the US Food & Drug Administration.]]>https://www.globenewswire.com/news-release/2023/03/27/2634634/0/en/Todos-Medical-Begins-Trading-on-the-OTC-Pink-Marketplace.html?f=22&fvtc=4&fvtv=45088Todos Medical Begins Trading on the OTC Pink Marketplace2023-03-27T11:16:08Z<![CDATA[New York, NY, Alpharetta, GA, Tel Aviv, ISRAEL, March 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Ordinary shares will begin trading on the OTC Pink marketplace beginning on March 27, 2023 as a result of the Company’s closing bid price falling below $0.001 for 5 consecutive trading days, from March 20, 2023 through March 24, 2023.]]>https://www.globenewswire.com/news-release/2023/03/15/2628107/0/en/Todos-Medical-Supports-Long-COVID-Awareness-Day.html?f=22&fvtc=4&fvtv=45088Todos Medical Supports Long COVID Awareness Day2023-03-15T18:27:46Z<![CDATA[NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced its support for International Long COVID Awareness Day. Todos Medical is fully aligned with the Long COVID community and its effort to boost awareness, as well as calls for additional resources to be invested to fight this potentially debilitating condition.]]>https://www.globenewswire.com/news-release/2023/03/13/2626253/0/en/Todos-Medical-Enters-Into-Moratorium-on-Conversions-Agreement-With-Convertible-Note-Holders.html?f=22&fvtc=4&fvtv=45088Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders2023-03-13T23:26:11Z<![CDATA[Moratorium Goes Into Effect After Market Close on March 13, 2023]]>https://www.globenewswire.com/news-release/2023/02/23/2614554/0/en/Todos-Medical-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=45088Todos Medical Provides Corporate Update2023-02-23T15:30:40Z<![CDATA[New York, NY, and Tel Aviv, ISRAEL, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today provided a corporate update for shareholders.]]>Todos Medical Ltd. TOMDFhttps://www.globenewswire.com/news-release/2023/02/14/2607743/0/en/Todos-Medical-Initiates-Validation-Plan-for-PCR-based-Avian-Influenza-A-H5N1-Bird-Flu-Test-at-CLIA-CAP-Testing-Lab-Provista-Diagnostics.html?f=22&fvtc=4&fvtv=45088Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics2023-02-14T14:06:55Z<![CDATA[New York, NY, and Tel Aviv, ISRAEL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based Avian Influenza A (H5N1, bird flu) human testing. Under the plan, the Company will validate commercial and internally developed H5N1 PCR reagents and launch the most sensitive test. The H5N1 PCR test is being developed as a Laboratory Developed Test (LDT).]]>https://www.globenewswire.com/news-release/2022/12/06/2568518/0/en/Todos-Medical-to-Present-at-the-RHK-2022-Disruptive-Growth-Conference.html?f=22&fvtc=4&fvtv=45088Todos Medical to Present at the RHK 2022 Disruptive Growth Conference2022-12-06T15:10:39Z<![CDATA[New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be presenting at the RHK 2022 Disruptive Growth Conference on Tuesday, December 6th at 12:20pm ET.]]>